AliveCor v. Apple: Federal Circuit Affirms ECG Patent Unpatentable
AliveCor’s appeal to the Federal Circuit over US10638941B2 — a patent covering discordance monitoring in ECG wearables — ended in affirmance after 751 days. The Federal Circuit found no reversible error, leaving Apple’s position intact and the patent cancelled. Quinn Emanuel faced Fish & Richardson, Orrick, and White & Case in one of the most high-profile wearable health IP battles of recent years.
AliveCor’s ECG Patent Falls at the Federal Circuit After Apple Challenge
AliveCor, Inc. brought this appeal before the Court of Appeals for the Federal Circuit (Case No. 23-1514) on February 15, 2023, challenging a prior tribunal finding that US10638941B2 — a patent covering discordance monitoring in ECG wearable devices — was unpatentable. AliveCor had asserted this patent in connection with Apple Watch cardiac monitoring functionality, making it one of the most commercially significant wearable health disputes in recent U.S. IP history.
The Federal Circuit issued its order on March 7, 2025, affirming the unpatentability determination. The single-word disposition — AFFIRMED — confirms that the appellate panel found no reversible error in the lower proceeding’s patentability analysis. For AliveCor, the affirmance is dispositive: US10638941B2 is cancelled and no longer enforceable as a basis for infringement claims against Apple or any third party.
The 751-day appellate timeline — filed February 2023, resolved March 2025 — is consistent with complex Federal Circuit patent appeals involving full briefing and oral argument scheduling. The depth of Apple’s legal team (three law firms, six named counsel) suggests the company treated this appeal as a priority matter. What remains unknown from the public record is whether any licensing discussions occurred in parallel, or whether AliveCor has continuation or divisional applications in prosecution that could revive comparable claims.
Filing to Unpatentable in 751 days
751 days — above-average duration for a Federal Circuit patent appeal
Federal Circuit affirms: what the unpatentability ruling means for both parties
What ‘AFFIRMED’ means at the Federal Circuit level
An affirmance by the Federal Circuit means the appellate panel reviewed the lower tribunal’s patentability determination and found no reversible legal or factual error. The lower ruling stands in full. AliveCor exhausted its appeal at this level; the unpatentability finding is now final unless AliveCor petitions the Supreme Court for certiorari — a step granted in only a small fraction of patent cases.
No reversible error foundAliveCor loses its ECG discordance patent permanently
For AliveCor, the affirmance is the worst possible appellate result. US10638941B2 is unpatentable, removing it from AliveCor’s enforcement toolkit entirely. The company can no longer assert this patent against Apple Watch or any competitor’s wearable ECG product. Commercial leverage in any licensing negotiation tied to this patent is extinguished. Strategic options now depend on continuation filings or new patent development around the same underlying technology.
Patent cancelled — unenforceableApple secures freedom to operate on ECG discordance features
Apple’s three-firm legal team prevailed across both the lower proceeding and the Federal Circuit appeal. With US10638941B2 cancelled, Apple faces no liability exposure on this patent for Apple Watch ECG functionality. The affirmance also raises the bar significantly for AliveCor to mount a fresh challenge using related claims, as the Federal Circuit’s analysis of the prior art landscape is now established precedent in this dispute.
FTO confirmed for Apple Watch ECGWearable ECG IP landscape shifts in Apple’s favour
The Federal Circuit’s affirmance strengthens Apple’s position in the broader wearable cardiac monitoring IP environment. Competitors and patent holders in the ECG wearable space — including companies developing discordance detection algorithms — face a precedent suggesting these claim formulations may be vulnerable to unpatentability challenges. R&D and IP teams in the sector should audit related portfolios for similar claim structures before asserting or relying on them commercially.
Higher invalidity risk for ECG wearable patentsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AliveCor, Inc. | Company | Wearable cardiac monitoring company — holder of US10638941B2Search in Eureka ↗ |
| Defendant | Apple, Inc. | Company | Apple, Inc. — consumer electronics and wearables maker, Apple Watch ECG feature at issueSearch in Eureka ↗ |
| Plaintiff counsel | Sean S. Pak | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William Adams | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Defendant counsel | Benjamin Elacqua | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark S. Davies | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Melanie L. Bostwick | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael Ari Amon | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Ruffin B. Cordell | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Walter Karl Renner | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson PC | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Orrick, Herrington & Sutcliffe LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | White & Case LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ — is unqualified and dispositive. No remand, no partial reversal, no claim-by-claim carve-out. The panel reviewed the unpatentability determination in its entirety and found the lower tribunal’s analysis legally and factually sound under the applicable appellate standard, which typically requires clear error for factual findings and de novo review for legal questions of patentability. For AliveCor, there is no residual foothold: the patent is cancelled with appellate finality at the circuit level.
US10638941B2 — ECG Discordance Monitoring for Wearable Cardiac Devices
US10638941B2, filed under application number US16/158112, protects technology relating to discordance monitoring in the context of electrocardiogram (ECG) wearable devices. Discordance monitoring refers to the detection of mismatches or anomalies between expected and measured cardiac signals — a clinically significant capability in consumer-grade wearables designed to flag potential arrhythmias. The patent sits at the intersection of medical-grade signal processing and consumer hardware, a technically complex domain where prior art boundaries are fiercely contested.
Strategically, US10638941B2 was central to AliveCor’s effort to carve out IP space around Apple Watch’s ECG features — one of the most commercially successful wearable health functions ever shipped at consumer scale. The Federal Circuit’s affirmance of unpatentability removes this particular claim set from the competitive landscape permanently, but the underlying technical domain remains highly active. Companies developing ECG wearables, discordance algorithms, or cardiac rhythm analytics should treat this case as a signal that claim specificity and prior art differentiation are critical to patent survivability in this category.
Should you run an FTO analysis against US10638941B2 and related ECG wearable patents?
Any company developing wearable ECG products, cardiac discordance detection algorithms, or Apple Watch-adjacent health monitoring features should treat this case as a trigger for FTO review — not just of US10638941B2 (now cancelled) but of the broader AliveCor patent family and related third-party ECG monitoring IP. The cancellation of one patent does not clear the landscape; continuation filings and related applications from the same family may still pose enforcement risk.
PatSnap Eureka’s FTO Search Agent can map the full US16/158112 patent family, identify live continuation applications, surface prior art cited in this proceeding, and benchmark your product’s feature set against active claim language in the ECG wearable space. R&D and IP teams building cardiac monitoring features into consumer devices should run this analysis before product launch — not after receiving a cease-and-desist.
Run a freedom-to-operate analysis on US10638941B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ECG and Wearable Health Patent Appeal Cases
Federal Circuit appeals involving ECG wearable patents and unpatentability challenges — cases most relevant to the AliveCor v. Apple cardiac monitoring dispute.
What this case signals for the wearable cardiac monitoring IP landscape
AliveCor v. Apple is a landmark data point for ECG wearable patent strategy — with implications for enforcement, portfolio building, and FTO.
ECG wearable patents face heightened unpatentability risk post-affirmance
The Federal Circuit’s affirmance confirms that discordance monitoring claim structures in ECG wearables are susceptible to prior art challenges. Patent holders in this space should audit their portfolios now — claims drafted similarly to US10638941B2 may be vulnerable. Prosecution teams should prioritise claim differentiation against the prior art record established in this proceeding.
Apple’s three-firm defence model sets a benchmark for high-stakes wearable IP
Apple deployed Fish & Richardson, Orrick, and White & Case simultaneously — a resource commitment that signals how seriously it treats ECG-related patent threats to Apple Watch. In-house IP teams at wearable health companies should treat Apple as an exceptionally well-resourced defendant in any enforcement strategy, with the capacity to pursue IPR, district court defence, and Federal Circuit appeal in parallel.
AliveCor v Apple — key questions answered
The Federal Circuit affirmed the lower tribunal’s finding that US10638941B2 is unpatentable. The March 7, 2025 order is unqualified — no remand or partial reversal. US10638941B2, covering ECG discordance monitoring technology, is permanently cancelled and unenforceable. AliveCor’s appeal did not succeed at the circuit level.
US10638941B2 (application US16/158112) protects ECG discordance monitoring technology — the detection of mismatches or anomalies in cardiac signal readings in wearable devices. AliveCor asserted this patent in connection with Apple Watch’s ECG functionality, which allows users to take medical-grade heart rhythm readings. The patent was central to AliveCor’s IP strategy for monetising its cardiac monitoring innovations against Apple’s consumer hardware ecosystem.
An affirmance by the Federal Circuit means the appellate panel reviewed the lower tribunal’s determination and found no reversible error — neither legal nor factual. The lower ruling stands without modification. In this case, the unpatentability finding against US10638941B2 was affirmed in full, making it final at the circuit level. AliveCor’s remaining option would be a petition for certiorari to the U.S. Supreme Court, which is granted only rarely.
The ruling directly cancels only US10638941B2. However, the Federal Circuit’s affirmance of the prior art analysis creates persuasive precedent for future challenges to similarly drafted ECG discordance monitoring claims. Companies in the wearable cardiac monitoring space should assess whether their own patents or those they rely on share structural similarities with the cancelled claims, as they may face elevated invalidity risk in subsequent IPR proceedings.
AliveCor was represented by Quinn Emanuel Urquhart & Sullivan, LLP, with Sean S. Pak and William Adams as named counsel. Apple assembled a three-firm defence team comprising Fish & Richardson PC, Orrick Herrington & Sutcliffe LLP, and White & Case LLP, with six named counsel including Benjamin Elacqua, Ruffin B. Cordell, and Mark S. Davies, among others. The size of Apple’s legal team is consistent with the commercial significance of the Apple Watch ECG feature at issue.
PatSnap Eureka searches patents and litigation data to answer instantly.